Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax has completed the first part of its phase III clinical trial for DX-88 in the treatment of hereditary angioedema and the drug has received broadened fast track designation from the FDA.
Subscribe to our email newsletter
The broadened designation includes all types of acute hereditary angioedema (HAE) attacks. HAE is a rare and life-threatening inflammatory condition for which there is no approved therapy in the US.
The trial is designed to determine the efficacy of DX-88 for patients suffering from moderate to severe acute HAE attacks. The trial is comprised of two phases, a double-blind, placebo-controlled phase which is now complete, and a repeat dosing phase. The second phase of the study will continue to treat patients and allows DX-88 to be administered for acute attacks.
“DX-88 has continued to demonstrate a good safety profile and has been well tolerated on single and multiple dosing,” said Henry Blair, chairman and CEO of Dyax.
Dyax has also successfully completed a phase I/II trial of DX-88 for the prevention of blood loss during on-pump CABG procedures.